Proxy Statement Pursuant to Section 14(a) of the
                         Securities Exchange Act of 1934
                                (Amendment No. )

Filed by the Registrant [X]

Filed by a Party other than the Registrant [  ]

Check the appropriate box:
                                               [  ] Confidential, for Use of the
[  ] Preliminary Proxy Statement                Commission Only (as Permitted by
                                                Rule 14a-6(e)(2))

[  ] Definitive Proxy Statement

[X] Definitive Additional Materials

[  ] Soliciting Material Pursuant to (S)240.14a-12

                           BIOMARIN PHARMACEUTICAL INC.
                 (Name of Registrant as Specified In Its Charter)

      (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

    (1) Title of each class of securities to which transaction applies:

    (2) Aggregate number of securities to which transaction applies:

    (3) Per unit price or other underlying value of transaction computed
    pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing
    fee is calculated and state how it was determined):

    (4) Proposed maximum aggregate value of transaction:

    (5) Total fee paid:

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.

    (1) Amount Previously Paid:

    (2) Form, Schedule or Registration Statement No.:

    (3) Filing Party:

    (4) Date Filed:

                      [BioMarin Pharmaceutical, Inc. Letterhead]

Dear Stockholder,

We recently mailed proxy materials  regarding the BioMarin  Pharmaceutical  Inc.
Annual  Meeting to be held on August  13,  2002.  The  proposed  transaction  to
acquire all of the  outstanding  Glyko  Biomedical  Ltd.  common  shares and the
election of six directors is very  important,  and according to our records your
vote has not been received.

Your shares cannot be voted unless you give your specific instructions and sign,
date, and return your proxy card.

BioMarin's  Board of  Directors  recommends  that  stockholders  vote  "FOR" the
transaction and the election of each of the nominees.

Your vote is extremely  important.  Please vote today,  using the enclosed proxy
card and return envelope.


/s/ Kim R. Tsuchimoto
Kim R. Tsuchimoto
Vice President, Controller